Bone Degeneration Therapeutics Market size was estimated at USD X Mn in 2021, growing at a CAGR of X% during the forecast period 2022-2028. Bone degeneration is characterized by the deterioration of articular cartilage casing the joints. Cartilage provides helps to free movement of joint without friction. Deterioration of the cartilage leads to the reduce in flexibility of joint movements and causes compressed nerve, inflammation, and pain. Bone degeneration is majorly occurs due to congenital disorders, injuries, diabetes, and obesity among others. Symptoms associated with bone degeneration include joint stiffness, numbness in case of bone spurs, pain in back, and joint inflammation. Global bone degeneration therapeutics market is segmented on the basis of drug type, rout of administration, application, distribution channel, and region. In October 2017, Flexion Therapeutics received FDA approval for Zilretta used in the treatment of osteoarthritis knee pain. The articular cartilage that covers the joints deteriorates with bone degeneration. Cartilage allows the joint to move freely and without resistance. Inflammation, squeezed nerves, and discomfort result from a reduction in joint flexibility caused by cartilage degeneration. Bone degradation is a normal process that is accelerated by a variety of factors such as traumas, congenital diseases, diabetes, and obesity. Joint stiffness, radiating pain that starts in the back and progresses to the limbs, and joint inflammation are all symptoms of degenerative bone problems.